Novel drug therapies in myelois leukemia: a patent review

Horne, G. A. , Kinstrie, R. and Copland, M. (2015) Novel drug therapies in myelois leukemia: a patent review. Pharmaceutical Patent Analyst, 4(3), pp. 187-205. (doi:10.4155/ppa.15.3) (PMID:26030080)

[img]
Preview
Text
106617.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Both acute myeloid leukemia and chronic myeloid leukemia are thought to arise from a subpopulation of primitive cells, termed leukemic stem cells that share properties with somatic stem cells. Leukemic stem cells are capable of continued self-renewal, and are resistant to conventional chemotherapy and are considered to be responsible for disease relapse. In recent years, improved understanding of the underlying mechanisms of myeloid leukemia biology has led to the development of novel and targeted therapies. This review focuses on clinically relevant patent applications and their relevance within the known literature in two areas of prevailing therapeutic interest, namely monoclonal antibody therapy and small molecule inhibitors in disease-relevant signaling pathways.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Horne, Dr Gillian and Kinstrie, Dr Ross and Copland, Professor Mhairi
Authors: Horne, G. A., Kinstrie, R., and Copland, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Pharmaceutical Patent Analyst
Publisher:Future Science Ltd.
ISSN:2046-8954
ISSN (Online):2046-8962
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in Pharmaceutical Patent Analyst 4(3):187-205
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
618571The importance of the Notch pathway and its interaction in the maintenance and progression of chronic myeloid leukaemiaMhairi CoplandWellcome Trust (WELLCOME)100626/Z/12/ZICS - PAUL O'GORMAN LEUKAEMIA RESEARCH C